139 related articles for article (PubMed ID: 7768774)
41. Reevaluation of fosfomycin: clinical and laboratory studies.
Dai ZY; Zhang YY; Zhang MF; Zhang ZL; Zhang JD; Liu YK
Chin Med J (Engl); 1981 Oct; 94(10):645-52. PubMed ID: 6797798
[No Abstract] [Full Text] [Related]
42. [Effect of fosfomycin trometamol (Monuril) on skin flora, both qualitatively and with regard to induction of resistance].
Gismondo MR; Lo Bue AM; Nicoletti G
Ann Ist Super Sanita; 1987; 23(4):787-92. PubMed ID: 3452286
[No Abstract] [Full Text] [Related]
43. Fosfomycin: mechanisms and the increasing prevalence of resistance.
Aghamali M; Sedighi M; Zahedi Bialvaei A; Mohammadzadeh N; Abbasian S; Ghafouri Z; Kouhsari E
J Med Microbiol; 2019 Jan; 68(1):11-25. PubMed ID: 30431421
[TBL] [Abstract][Full Text] [Related]
44. [Treatment of acute cystitis: cost-effectiveness analysis of the single dose versus conventional therapy].
Capri S; Del Bono GP
G Ital Chemioter; 1991; 38(1-3):163-4. PubMed ID: 1365579
[No Abstract] [Full Text] [Related]
45. [A study on the disc sensitivity test for fosfomycin (author's transl)].
Kanazawa Y; Kuramata T; Matsumoto K
Jpn J Antibiot; 1982 Mar; 35(3):794-800. PubMed ID: 7097982
[TBL] [Abstract][Full Text] [Related]
46. Fosfomycin: an old--new antibiotic.
Raz R
Clin Microbiol Infect; 2012 Jan; 18(1):4-7. PubMed ID: 21914036
[TBL] [Abstract][Full Text] [Related]
47. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
[TBL] [Abstract][Full Text] [Related]
48. The influence of anaerobiosis on the activity of fosfomycin trometamol.
Greenwood D; Brown J; Edwards R
Infection; 1992; 20 Suppl 4():S305-9. PubMed ID: 1294523
[TBL] [Abstract][Full Text] [Related]
49. [Fosfomycin susceptibility of clinical isolates from otorhinolaryngological infections].
Deguchi K
Jpn J Antibiot; 1983 Oct; 36(10):2844-8. PubMed ID: 6674519
[TBL] [Abstract][Full Text] [Related]
50. Fosfomycin: Laboratory studies.
Woodruff HB; Mata JM; Hernández S; Mochales S; Rodríguez A; Stapley EO; Wallick H; Miller AK; Hendlin D
Chemotherapy; 1977; 23 Suppl 1():1-22. PubMed ID: 583866
[TBL] [Abstract][Full Text] [Related]
51. Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.
Falagas ME; Athanasaki F; Voulgaris GL; Triarides NA; Vardakas KZ
Int J Antimicrob Agents; 2019 Jan; 53(1):22-28. PubMed ID: 30268576
[TBL] [Abstract][Full Text] [Related]
52. [Antibacterial activity of fosfomycin against the causative bacteria isolated from bacterial enteritis].
Fukuyama M; Furuhata K; Oonaka K; Hara T; Sunakawa K
Jpn J Antibiot; 2000 Jul; 53(7):522-31. PubMed ID: 11019386
[TBL] [Abstract][Full Text] [Related]
53. Studies on phosphonic acid antibiotics. IV. Synthesis and antibacterial activity of analogs of 3-(N-acetyl-N-hydroxyamino)-propylphosphonic acid (FR-900098).
Hemmi K; Takeno H; Hashimoto M; Kamiya T
Chem Pharm Bull (Tokyo); 1982 Jan; 30(1):111-8. PubMed ID: 7083400
[No Abstract] [Full Text] [Related]
54. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
[TBL] [Abstract][Full Text] [Related]
55. [In vitro antibacterial activity of fosfomycin].
Giola L; Rizzu D; Zanetti S
G Batteriol Virol Immunol; 1979; 71(1-6):34-40. PubMed ID: 385409
[TBL] [Abstract][Full Text] [Related]
56. In vitro testing of the antibacterial activity of fosfomycin trometamol against urinary pathogens.
Rossi L; Fontana R; Meloni GA
Chemioterapia; 1988 Feb; 7(1):10-4. PubMed ID: 3259908
[TBL] [Abstract][Full Text] [Related]
57. [Comparative study of the antibacterial activity of water and ether extracts of fosfomycin and azidocillin].
Pase U; Fusetti F; Nicolin T
G Stomatol Ortognatodonzia; 1983; 2(2):57-9. PubMed ID: 6441786
[No Abstract] [Full Text] [Related]
58. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria.
Dinh A; Salomon J; Bru JP; Bernard L
Scand J Infect Dis; 2012 Mar; 44(3):182-9. PubMed ID: 22176655
[TBL] [Abstract][Full Text] [Related]
59. [Conditions influencing the activity of fosfomycin in vitro (author's transl)].
Haag R; Vömel W
Immun Infekt; 1979 Dec; 7(6):202-9. PubMed ID: 396228
[TBL] [Abstract][Full Text] [Related]
60. Inability of gentamicin and fosfomycin to eliminate intracellular Enterobacteriaceae.
Kihlström E; Andåker L
J Antimicrob Chemother; 1985 Jun; 15(6):723-8. PubMed ID: 4030534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
